CN114796497A - 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物 - Google Patents

治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物 Download PDF

Info

Publication number
CN114796497A
CN114796497A CN202210537585.5A CN202210537585A CN114796497A CN 114796497 A CN114796497 A CN 114796497A CN 202210537585 A CN202210537585 A CN 202210537585A CN 114796497 A CN114796497 A CN 114796497A
Authority
CN
China
Prior art keywords
ifp35
nmi
activity
disease
nid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210537585.5A
Other languages
English (en)
Chinese (zh)
Inventor
刘迎芳
梁欢欢
沈涓
夏侯志楷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Yingenmai Biomedical Technology Co ltd
Original Assignee
Guangzhou Yingenmai Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Yingenmai Biomedical Technology Co ltd filed Critical Guangzhou Yingenmai Biomedical Technology Co ltd
Publication of CN114796497A publication Critical patent/CN114796497A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
CN202210537585.5A 2014-08-22 2015-08-21 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物 Pending CN114796497A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201410418773 2014-08-22
CN2014104187731 2014-08-22
PCT/CN2015/000602 WO2016026258A1 (en) 2014-08-22 2015-08-21 Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins
CN201580045210.5A CN107427552B (zh) 2014-08-22 2015-08-21 防治与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580045210.5A Division CN107427552B (zh) 2014-08-22 2015-08-21 防治与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物

Publications (1)

Publication Number Publication Date
CN114796497A true CN114796497A (zh) 2022-07-29

Family

ID=55350147

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202210537585.5A Pending CN114796497A (zh) 2014-08-22 2015-08-21 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
CN202210537590.6A Pending CN115054687A (zh) 2014-08-22 2015-08-21 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
CN201580045210.5A Active CN107427552B (zh) 2014-08-22 2015-08-21 防治与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202210537590.6A Pending CN115054687A (zh) 2014-08-22 2015-08-21 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
CN201580045210.5A Active CN107427552B (zh) 2014-08-22 2015-08-21 防治与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物

Country Status (5)

Country Link
US (4) US11466061B2 (https=)
EP (1) EP3182990A4 (https=)
JP (1) JP6968696B2 (https=)
CN (3) CN114796497A (https=)
WO (1) WO2016026258A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016026258A1 (en) 2014-08-22 2016-02-25 Institute Of Biophysics, Chinese Academy Of Sciences Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins
CN118767136A (zh) * 2019-04-01 2024-10-15 广州恩迈生物科技有限公司 慢性炎症的诊断和治疗
CN110669765B (zh) * 2019-11-04 2022-11-01 中国科学院水生生物研究所 鳜干扰素诱导蛋白启动子和应用
CN113234153B (zh) * 2021-04-07 2022-12-20 中山大学 一批识别ifp35家族蛋白的单克隆抗体及其在免疫识别等方面的应用
CN118667938A (zh) * 2021-07-09 2024-09-20 广州恩迈生物科技有限公司 Ifp35和/或nmi在诊治疾病中的应用
CN116239685A (zh) * 2023-02-24 2023-06-09 中山大学·深圳 一种识别ifp35蛋白的抗体及其应用
EP4682166A1 (en) * 2023-04-10 2026-01-21 Guangzhou Enmai Biotechnology Co., Ltd Anti-nmi monoclonal antibody or antigen-binding fragment thereof, and use thereof
CN120536560A (zh) * 2024-02-19 2025-08-26 中山大学·深圳 Ifp35家族蛋白在诊断脓毒症或其相关疾病中的应用
CN120842381A (zh) * 2025-07-22 2025-10-28 中山大学 一种识别nmi蛋白的单克隆抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028460A2 (en) * 1997-12-03 1999-06-10 Leadd B.V. Molecules interacting with apoptin
CN1703523A (zh) * 2002-09-30 2005-11-30 肿瘤疗法科学股份有限公司 诊断前列腺癌的方法
CN101473045A (zh) * 2006-04-24 2009-07-01 健泰科生物技术公司 用于检测自身免疫性病症的方法和组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
EP1807540A4 (en) * 2004-11-05 2008-12-10 Us Gov Sec Navy DIAGNOSIS AND PROGNOSIS OF CLINICAL PHENOTYPES OF INFECTION DISEASES AND OTHER PHYSIOLOGICAL CONDITIONS USING GENE EXPRESSION OF A HOSTS AS BIOMARKERS IN THE BLOOD
RU2008117085A (ru) * 2005-10-03 2009-11-10 Новартис АГ (CH) Консервативный мембранный активатор кальциневрина (смас), новый терапевтический белок и мишень
FR2892730A1 (fr) * 2005-10-28 2007-05-04 Biomerieux Sa Methode pour detecter la presence ou le risque de developper un cancer
NZ573052A (en) * 2006-04-26 2012-03-30 Vertex Pharma Hepatitis c virus infection biomarkers
KR101326367B1 (ko) * 2006-07-03 2013-11-11 가톨릭대학교 산학협력단 항암제 저항성의 진단 방법 및 진단 키트
AU2007286915B2 (en) 2006-08-11 2014-05-15 Baylor Research Institute Gene expression signatures in blood leukocytes permit differential diagnosis of acute infections
EP2170311A4 (en) * 2007-05-16 2011-10-19 Avalon Pharmaceuticals COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
WO2016026258A1 (en) 2014-08-22 2016-02-25 Institute Of Biophysics, Chinese Academy Of Sciences Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins
CN118767136A (zh) 2019-04-01 2024-10-15 广州恩迈生物科技有限公司 慢性炎症的诊断和治疗

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028460A2 (en) * 1997-12-03 1999-06-10 Leadd B.V. Molecules interacting with apoptin
CN1703523A (zh) * 2002-09-30 2005-11-30 肿瘤疗法科学股份有限公司 诊断前列腺癌的方法
CN101473045A (zh) * 2006-04-24 2009-07-01 健泰科生物技术公司 用于检测自身免疫性病症的方法和组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAS A ET AL.: "Interferon-inducible protein IFI35 negatively regulates RIG-I antiviral signaling and supports vesicular stomatitis virus replication" *
JIE WANG ET AL: "Negative Regulation of Nmi on Virus-Triggered Type I IFN Production by Targeting IRF7" *
JUAN TAN ET AL: "IFP35 Is Involved in the Antiviral Function of Interferon by Association with the Viral Tas Transactivator of Bovine Foamy Virus" *
XIANGJUN ZHOU ET AL: "Interferon- a Induces Nmi-IFP35 Heterodimeric Complex Formation That Is Affected by the Phosphorylation of IFP35" *

Also Published As

Publication number Publication date
US20250084137A1 (en) 2025-03-13
JP2017528129A (ja) 2017-09-28
US20180037617A1 (en) 2018-02-08
EP3182990A4 (en) 2018-04-11
WO2016026258A1 (en) 2016-02-25
JP6968696B2 (ja) 2021-11-17
US20250059242A1 (en) 2025-02-20
CN107427552A (zh) 2017-12-01
EP3182990A1 (en) 2017-06-28
CN115054687A (zh) 2022-09-16
US20230265135A1 (en) 2023-08-24
CN107427552B (zh) 2022-12-20
US11466061B2 (en) 2022-10-11

Similar Documents

Publication Publication Date Title
CN107427552B (zh) 防治与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
JP7536737B2 (ja) Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
CN110621338B (zh) 广谱中和抗hiv-1抗体及其使用方法
JP7716992B2 (ja) 骨髄細胞炎症性表現型を調節するための抗ｐｓｇｌ－１組成物及び方法、ならびにその使用
KR20190003958A (ko) 암의 치료 및 모니터링 방법
KR20180119632A (ko) 암에 대한 치료 및 진단 방법
JP6416117B2 (ja) Ｊａｇｇｅｄ１に結合する抗体
HK1216428A1 (zh) 血小板衍生生长因子b之特异性抗体及其组合物和用途
BR112014006175B1 (pt) Anticorpos capazes de neutralisar as exotoxinas principais tcda e tcdb de clostridium difficile
TW201219568A (en) Antibody targeting osteoclast-related protein Siglec-15
WO2017147368A1 (en) Redirecting immune responses
CN111116743B (zh) Hsp90抗体及其在抗真菌感染中的应用
KR20230017778A (ko) 골수성 세포 염증성 표현형을 조절하기 위한 항-vsig4 조성물 및 방법, 그리고 이의 용도
CN112996815B (zh) 人pd-l1抗体
CN119630421A (zh) 用于治疗癌症的抗pd-1活性剂、抗tim-3活性剂和抗lag-3活性剂的组合疗法
CN117177770A (zh) 使用抗tigit抗体与抗pd1抗体组合治疗癌症的方法
JP2023531200A (ja) 抗ｔｉｇｉｔ抗体及びｐｄ－１軸結合アンタゴニストを用いた治療
AU2019235652B2 (en) Bispecific antibodies to MOSPD2 and T cell- or NK cell-specific molecules
JPWO2014061783A1 (ja) クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片
JP2018534915A5 (https=)
CN116606373A (zh) 新型冠状病毒中和抗体及其用途
CN102711772A (zh) Artemin拮抗剂的抗肿瘤用途
TW201716439A (zh) Ｈｅｒ３抗體
CN116917315A (zh) 用于治疗甲型流感感染的抗体和方法
WO2024026496A1 (en) Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination